Articles

SLS009 is a novel CDK9 inhibitor under investigation for the treatment of relapsed/refractory peripheral T-cell lymphomas.

FDA Grants Fast Track Designation to Sellas Life Sciences’ SLS009 for Lymphoma

Exagamglogene autotemcel (exa-cel) has shown the potential to be a landmark therapy in preventing episodes of excruciating pain among patients with sickle cell disease.

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel for Severe Sickle Cell Disease

The branded form of secukinumab is currently the only FDA-approved fully human biologic that directly inhibits interleukin-17A.

FDA Approves Cosentyx as Treatment Option for Hidradenitis Suppurativa 

Abatacept is indicated across multiple inflammatory conditions, including for the treatment of adult patients with moderately to severely active rheumatoid arthritis, pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis, and active juvenile psoriatic arthritis.

FDA Approves Expanded Indication for Abatacept to Treat Juvenile Psoriatic Arthritis

Furmonertinib is in development for the treatment of advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.

Arrivent’s Furmonertinib Receives FDA Breakthrough Therapy Designation

The FDA granted Wezlana with interchangeable designation after clinical trials found no clinically significant differences in safety and efficacy for the indicated conditions across multiple inflammatory diseases.

FDA Approves Interchangeable Ustekinumab Biosimilar for Inflammatory Diseases

The approval of pembrolizumab (Keytruda; Merck) combined with gemcitabine and cisplatin for the treatment locally advanced unresectable or metastatic biliary tract cancer is the sixth sixth indication for the anti-PD-1 therapy for gastrointestinal cancers. 

FDA Approves Keytruda Plus Chemotherapy for Biliary Tract Cancer

MarketsandMarkets report points to growth of over $3 billion over the next five years.

Pharma Packaging Equipment Market Expected to Reach Over $12 Billion 

The latest people news happenings over the past month.

People Spotlight — October 2023

Effort displays the diverse perspectives, skills, and people involved with the healthcare supply chain, as industry aims to continue to push DE&I forward.

News